Russian Regions With Highest Smoking Rates in 2021

Aug.12.2022
Russian Regions With Highest Smoking Rates in 2021
Novgorod, St. Petersburg, and Krasnodar have the highest number of smokers in Russia according to a digital tagging experiment.

In terms of population, Novgorod Region, St. Petersburg, and Krasnodar Border Zone have the highest number of smokers since the introduction of the electronic cigarette marking experiment at the beginning of this year.


The analysts of the National Digital Label System have drawn these conclusions based on their own statistical data on packaging sales volume and Rosstat data on the number of permanent residents in the Russian Federation.


According to these data, since the beginning of this year, each resident in the Novgorod region has purchased 4.4 packs of cigarettes, while in St. Petersburg the figure stands at 3.96 packs and in the Krasnodar border region, it is 3.42 packs.


The top 10 regions with the highest smoking rates include Magadan Oblast (2.65), Kamchatka Krai (2.09), Sakhalin (1.96), and Ryazan Oblast (1.92), as well as Moscow (1.84), Crimea (1.74), and Sevastopol (1.49).


According to a public opinion poll conducted by VTsIOM in July, 33% of adult citizens in Russia smoke today.


When analyzing the numbers behind the "honesty mark," it should be considered that in terms of tobacco regulation compliance, "smokers" are primarily the most honest and transparent regions. These leaders may not be the most active tobacco consumers, but they are certainly the most law-abiding.


Statement:


This article is compiled from third-party information and is intended for industry exchange and learning purposes only.


This article does not necessarily reflect the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of its contents. The translation of this article is solely for industry research and exchange.


Due to limitations in the translator's ability, the translated article may not convey the exact meaning of the original. Please refer to the original text for accuracy.


2FIRSTS is fully aligned with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or international statements and positions.


The ownership of compiled information belongs to the original media and author. If any infringement is found, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul Labs has asked a U.S. federal court to prevent NJOY and Altria from using documents stored in a public UCSF database in an ongoing patent lawsuit, arguing they are protected by attorney–client privilege. The defendants say the files have long been public and may contain evidence relevant to Juul’s patent conduct.
Dec.29 by 2FIRSTS.ai
TGA Sets 2026–2027 Compliance Principles, Flags Vaping Goods as a 2026 Priority
TGA Sets 2026–2027 Compliance Principles, Flags Vaping Goods as a 2026 Priority
The Therapeutic Goods Administration (TGA) has released its Compliance Principles for 2026 and 2027.Among 12 therapeutic goods categories identified for priority compliance and enforcement activity, TGA includes vaping goods, and it plans a further review of these priorities in March 2026.
Jan.23 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11
Philip Morris Korea launches TEREA “Shine Pearl” for IQOS ILUMA, expands capsule range to seven variants
Philip Morris Korea launches TEREA “Shine Pearl” for IQOS ILUMA, expands capsule range to seven variants
Philip Morris Korea said on Feb. 5 it has introduced “TEREA Shine Pearl,” a new TEREA stick designed for the IQOS ILUMA heated-tobacco device. The company said the product delivers a cool sensation and adds a fresh, fruity note when the capsule is crushed, bringing TEREA’s capsule-based lineup in South Korea to seven variants.
Feb.05 by 2FIRSTS.ai
Irish Vape Group Urges Full Scrutiny of Single-Use Vape Bill
Irish Vape Group Urges Full Scrutiny of Single-Use Vape Bill
Responsible Vaping Ireland (RVI) has urged TDs to fully scrutinise the Public Health (Single-Use Vapes) Bill 2025 as it comes before the Dáil for debate. Representing more than 3,300 independent vape retailers, RVI stressed that meaningful consultation with retailers and enforcement authorities is essential to ensure the ban meets its public health and environmental goals without unintended consequences.
Dec.17 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11